Although glutaminolysis is required for adequate T cell proliferation and cytokine secretion (126, 129), the GLS1 inhibitor CB839 - which is currently approved for phase 1B clinical trials - has shown minimal effects on CD4+ T cells at higher doses than those required for growth inhibition in cancer cells (125). The gene discussed is CD4; the disease is cancer.